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Abstract
Introduction Breast Cancer Prevention Trial (BCPT) and
Multiple Outcomes of Raloxifene (MORE) data have been
interpreted to indicate that tamoxifen reduces the risk of ER+
but not ER- breast carcinogenesis. We explored whether these
data also support an alternative hypothesis, that tamoxifen
influences the natural history of both ER+ and ER- cancers, that
it may be equally effective in abrogating or delaying ER- and
ER+ carcinogenesis, and place selection pressure, in some
cases, for the outgrowth of ER- cancers.
Methods BCPT and MORE data were used to investigate
whether: first, tamoxifen could reduce equally the emergence of
ER- and ER+ tumors; and second, tamoxifen could select a
fraction of emerging ER+ cancers and promote their
transformation to ER- cancers. Assuming that some proportion,
Z, of ER+ tumors becomes ER- after tamoxifen exposure and
that the risk reduction for both ER- and ER+ tumors is equal, we
solved for both the transformation rate and the risk reduction
rate.
Results If tamoxifen equally reduces the incidence of ER+ and
ER- tumors by 60%, the BCPT results are achieved with a
transformation of approximately Z = 20% of ER+ to ER- tumors.
Validation with MORE data using an equal risk reduction of 60%
associated with tamoxifen produces an almost identical
transformation rate Z of 23%.
Conclusion Data support an alternative hypothesis that
tamoxifen may promote ER- carcinogenesis from a precursor
lesion that would otherwise have developed as ER+ without
tamoxifen selection.
Introduction
The prevailing wisdom is that tamoxifen and other antiestro-
gens are active in preventing the development or progression
of estrogen receptor positive (ER+) breast cancers only. Effi-
cacy of tamoxifen for ER+ breast cancer has been clearly dem-
onstrated in both metastatic and adjuvant settings. The benefit
from adjuvant tamoxifen therapy was restricted to ER+ breast
cancers in the Early Breast Cancer Trialists' meta-analysis [1].
Tamoxifen does not inhibit proliferation of estrogen receptor
negative (ER-) breast cancer cell lines in tissue culture or in
murine xenograft models [1,2]. Recently, Allred et al. [3] tested
a subset of patients from the National Surgical Adjuvant
Breast and Bowel Project (NSABP) B-24 trial and demon-
strated that the effectiveness of tamoxifen following lumpec-
tomy and radiotherapy for ductal carcinoma in situ was limited
to ER+ in situ cancers. Thus, it was not at all unexpected that
results from the NSABP P-01 Breast Cancer Prevention Trial
(BCPT), the study of tamoxifen use versus placebo, fit the par-
adigm that tamoxifen prevents ER+ tumors. Women in the
tamoxifen arm of the BCPT trial developed ER+ tumors at an
annual incidence that was 69% less than that of the placebo
arm (5.02/1000 annually in placebo arm versus 1.58/1000
annually in tamoxifen arm). However, the incidence of ER-
tumor development was not significantly different between the
tamoxifen and placebo arms [4].
Evidence that tamoxifen efficacy in both the adjuvant and met-
astatic settings is limited to ER+ tumors does not exclude the
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possibility that, in the prevention setting, this drug could
reduce both ER+ and ER- tumorigenesis and mediate con-
comitantly a selection pressure for emergence of ER- tumors
in susceptible neoplastic cell subpopulations. In the NSABP
B-18, B-22 and B-25 studies, women under 50 years old were
not offered tamoxifen and all women over 50 years old
received tamoxifen. Long term follow up of these studies sug-
gests that tamoxifen exposure resulted in a higher likelihood
that subsequent contralateral breast cancer would be ER-
when compared to women who did not receive tamoxifen. The
conventional interpretation of these data implies that the
increased incidence of ER- tumors is a result of chemopreven-
tion of ER+ tumors by tamoxifen. It is possible, however, that
the observed data can be explained through another
mechanism.
The distribution of the ER+ or ER- second primary cancers
conditional on the estrogen receptor (ER) status of the first
breast primary from long term follow-up of the 5,513 patients
from NSABP studies B-18, B-22, and B25 is shown in Table
1. When these studies were initiated, it was standard to treat
all postmenopausal women with hormone therapy, regardless
of ER status, but tamoxifen was not thought to be effective in
premenopausal women. Therefore, in the NSABP trials B-18,
B-22, and B25, all postmenopausal women were treated with
tamoxifen, but none of the premenopausal women (at base-
line) were, allowing the opportunity to examine whether
tamoxifen might affect the ER status of tumors that developed
subsequently. Interestingly, of the women aged >50 years
with ER+ primary breast cancer who received adjuvant
tamoxifen and went on to develop a contralateral second pri-
mary, 44% of the cancers that developed were ER-. This is
substantially higher than the proportion of ER- second prima-
ries in the group of women aged <50 years who did not
receive adjuvant tamoxifen: only 11% of second primaries
were ER- when tamoxifen was not used [5]. Although the
number of second primaries arising in this very large initial
population was small, these data raise the possibility that
tamoxifen exposure could potentially select for subsequent
development of ER- cancers. These data challenged us to
explore an alternative hypothesis to explain the prevention trial
data. Data from the BCPT and the Multiple Outcomes of
Raloxifene (MORE) studies were used to examine whether
tamoxifen inhibits equally the emergence of ER- and ER+
tumors, but also promotes the transformation of a small pro-
portion of premalignant or neoplastic ER+ lesions to become
ER- tumors [5].
Methods
The data from the BCPT and MORE prevention trials are
shown in Table 2. In 1992, the NSABP began the P-01 BCPT
to determine if tamoxifen, an antagonist to estrogen in breast
tissue, was effective for breast cancer prevention. The study
included 13,338 high-risk postmenopausal women who had a
5 year Gail risk of 1.67% or higher and were aged 35 years or
older. Half were randomized to tamoxifen (6,681 women), and
the rest to placebo (6,707 women) and followed for a median
of 3.5 years [4]. The MORE study began in 1994 and explored
the effect of raloxifene on bone density in postmenopausal
women as a primary endpoint and the incidence of breast can-
cer as a secondary endpoint [6]. A total of 7,290 postmeno-
pausal women aged 80 years or younger with osteoporosis
were randomized to either raloxifene or placebo. The mean
age of study participants was 66 years. The number of ER- and
ER+ breast cancers that developed during each trial is given
in Table 2 for both the placebo and chemoprevention arms.
A mathematical model was constructed to support the hypoth-
esis that tamoxifen inhibits equally the development of ER- and
ER+ tumors, and also promotes the transformation of a pro-
portion of premalignant or neoplastic ER+ lesions to become
ER- tumors. The model was developed under these assump-
tions, with unknown rates of transformation and risk reduction
and was calibrated to match the observed data in these two
chemoprevention trials, the BCPT and the MORE. The
model's initial assumption was that tamoxifen reduced equally
the development of both ER- and ER+ tumors. Second, the
model assumed that some proportion, Z, of tumors that would
otherwise become ER+ in the absence of tamoxifen would
become ER- after exposure to tamoxifen. The tumors that
transform from ER+ to ER- would be de novo tamoxifen
resistant. The equations governing the model are shown in Fig.
1. The reference case assumes a 60% risk reduction for both
ER- and ER+ tumors, based on oophorectomy data that show
a 60% reduction in the risk of invasive breast cancer develop-
ment [7]. Using this value for the risk reduction, the model can
be used to solve for Z, the transformation rate to ER- tumors,
fitting the data from the NSABP and MORE trials.
Results
We assumed that if tamoxifen was equally effective in reducing
ER- and ER+ cancers, the risk reduction might approximate
that seen following oophorectomy in women with inherited
mutations in BRCA1/2. Based on data that oophorectomy
before the age of 40 years reduces the risk of invasive breast
Table 1
Exposure to tamoxifen appears to affect the conditional 
likelihood of the estrogen receptor status of subsequent 
contralateral primary breast cancers
ER status of tumors Tamoxifen treatment
First cancer Second cancer No Yes
ER- ER- 19 (70%) 7 (78%)
ER+ 8 (30%) 2 (22%)
ER+ ER- 4 (11%) 17 (44%)
ER+ 31 (89%) 22 (56%)
Data were taken from the National Surgical Adjuvant Breast and 
Bowel Project trials B-18, B-22, and B-25 [5]. ER, estrogen receptor.Available online http://breast-cancer-research.com/content/7/6/R1153
R1155
cancer development by approximately 60% [7], and solving for
the number of ER- and ER+ tumors in the BCPT that emerged
with and without therapy (Table 2), the transformation rate, Z,
required to fit the BCPT data is equal to 20.1%. A very similar
transformation rate of 22.7% is required to fit the MORE data
when one sets the risk reduction to 60% for all breast cancers
following tamoxifen use. Table 3 shows how the rate of trans-
formation from ER+ to ER- tumors varies with different
assumptions concerning the risk reduction from tamoxifen use.
The values for Z are surprisingly similar between the BCPT
and MORE data. Thus, we have demonstrated that the propor-
tion of ER- and ER+ tumors can be explained if we assume
that tamoxifen exposure results in an equal reduction in ER+
and ER- cancers but is also accompanied by the transforma-
tion to ER- of a small fraction of tumors that would otherwise
have remained as ER+.
Discussion
Mathematically, the BCPT and MORE data support the intrigu-
ing possibility that tamoxifen could exert an equal 60% risk
reduction on ER- and ER+ tumor development, if there was an
obligate transformation of approximately 20% of emerging
tumors from ER+ to ER- during tumorigenesis. It is noteworthy
that Kuukasjarvi and colleagues [8] have observed that
approximately 20% of ER+ primary tumors can recur with ER-
metastases even in the absence of medical therapy [8]. Similar
transformation rates of ER+ to ER- at relapse during adjuvant
tamoxifen therapy have also been reported [9,10].
There is also evidence that ER- cancers can emerge over time
after exposure to tamoxifen. ER+ primary tumors may recur as
ER- metastases in up to 20% of cases [8-10]. A recent meta-
analysis of patients with ER+ or progesterone receptor posi-
tive (PR+) primary tumors showed 22% (range 0.17 to 0.3) of
ER+ and 20% (range 0.2 to 0.33) of PR+ tumors recurred
with hormone receptor negative disease [11]. Interestingly,
prophylactic oophorectomy in BRCA1 and BRCA2 mutation
carriers under the age of 40 years causes a 60% reduction in
the risk of developing breast cancer. This is remarkable
because 80% of BRCA1 tumors are ER-. These observations
support the possibility that hormonal manipulations are effec-
tive in preventing the emergence of both ER+ and ER- tumors
[7,12]. King et al. [13], in their subset analysis of cases from
the BCPT, suggest that tamoxifen is effective in preventing
breast cancer in women with BRCA2  mutations, but not
BRCA1 mutations. Because the majority of BRCA1 tumors
are ER-, these data question our assumption that tamoxifen
does not prevent the outgrowth of ER- cancers. The number
of mutation carriers in the BCPT study was small enough, how-
ever, that it is difficult to draw conclusions about these data in
regards to our hypothesis; only 19 women were known to be
BRCA1 or BRCA2 mutation carriers in the BCPT (8 BRCA1
and 11 BRCA2). However, we do know that ovarian suppres-
sion (a different form of estrogen suppression) does reduce
the incidence of breast cancers in BRCA1 carriers. Further-
more, new data from Dr Narod's consortium suggest that
tamoxifen does indeed prevent the development of breast can-
cers in BRCA1 carriers whose tumors are primarily negative
(manuscript submitted; J. McClenann, personal
communication).
Atypia, which is reported to be uniformly ER+ [14], can pre-
cede ER- cancers. In the BCPT, 1,193 women with atypia
were entered into the study [4]. In the placebo and tamoxifen
arms, 23 and 3 cancers developed, respectively. Of the can-
cers that developed, 6/23 (26%) compared to 1/3 (33%)
Table 2
Chemoprevention appears to prevent ER+ cancers, but has no effect on ER- cancers
ER status Number of cancersa
Data from BCPT Data from MORE
Placebo (175 breast 
cancers developed)
Tamoxifen (89 breast 
cancers developed)
Placebo (39 breast 
cancers developed)
Raloxifene (22 breast 
cancers developed)
ER- 31 38 4 9
ER+ 130 41 31 10
aBecause the estrogen receptor (ER) status was not know for all cancers, the numbers do not add up to the totals. Data were taken from [4,6]. 
BCPT, Breast Cancer Prevention Trial; MORE, Multiple Outcomes of Raloxifene.
Figure 1
Equations used to test our alternative hypothesis Equations used to test our alternative hypothesis. Rate of ER- tumor 
development equals Z(ER+) + (ER-) × (1 - RR). Rate of ER+ tumor 
development equals (1 - Z) × (ER+) × (1 - RR). ER+, percentage of ER- 
tumors in absence of tamoxifen; ER-, percentage of ER+ tumors in 
absence of tamoxifen; RR, risk reduction from tamoxifen; Z, rate of 
transformation from ER+ to ER- tumors.
ER+ ER–
ER– ER+
Before Tamoxifen exposure
Z
After Tamoxifen exposure
(1–Z)×(1–RR) (1–RR)Breast Cancer Research    Vol 7 No 6    Esserman et al.
R1156
were ER- in the placebo and tamoxifen treated arm, respec-
tively. These numbers are too small to draw conclusions, but
they are not inconsistent with the theory that ER- cancers can
emerge from a previously ER+ preneoplastic cell population (J
Costantino, personal communication) [4]. Taken together,
these data suggest that exposure to tamoxifen could influence
the development of a small fraction of ER- tumors, and led us
to consider a reinterpretation of the prevention trial data.
Reduced levels of ER have been observed within 2 weeks of
starting neoadjuvant therapy with tamoxifen or raloxifene
[15,16], although the mechanism underlying this reduced
expression is unclear. In vitro, the binding of oestradiol to ERs
activates the transcriptional activity mediated by these recep-
tors and also leads to enhanced proteasomal degradation of
them [17-19]. It is possible that tamoxifen and raloxifene also
elicit ER proteolysis. These early changes in ER levels may
persist long-term and could lead to emergence of clinically
apparent ER- tumors from subclinical ER+ tumors during
tamoxifen or raloxifene therapy. These data and our modeling
raise the possibility that tamoxifen could inhibit proliferation of
both ER+ and ER- breast cancer cells but exert clonal selec-
tion for more proliferatively aggressive ER- clones during long-
term tamoxifen therapy.
Several molecular explanations have been proposed to
account for the emergence of the ER- breast cancer pheno-
type from tamoxifen treated ER+ breast cancers. ER point
mutations are too infrequent to account for the high frequency
of ER- breast cancers [20]. ER promoter hypermethylation is
seen in some ER- cell lines and, although this does not appear
to account for the ER- phenotype in most primary tumors, it
should not be discounted as a possible cause of treatment-
associated changes in ER phenotype. As it has been shown
that ER- primary breast cancer expresses ER mRNA [21-23],
it is possible that ER- tumors could arise through accelerated
ER proteolysis. An hypothesis for the transformation of ER+ to
ER- tumors during cancer progression may be that tamoxifen
selects for the outgrowth of a neoplastic or pre-malignant
breast cell subpopulation in which tamoxifen acts as a partial
agonist to stimulate ER proteolysis.
Tamoxifen resistance has also been shown to emerge from a
subpopulation in which epidermal growth factor receptor
(EGFR) and/or Her2 mitogenic signaling is hyperactived.
Transfection and activation of these receptors has been
shown to confer antiestrogen resistance in breast cancer lines
and xenografts [10,24,25]. Moreover, EGFR over-expression
and Her2 amplification are both correlated with ER negativity
in human breast cancers in vivo [26-29]. Data from the Slin-
gerland lab suggest that both EGFR and Her2 signaling can
cooperate with estrogen to activate ER proteolysis (I Chu, A
Alkarain, J Sun, manuscript submitted). Thus, tamoxifen in the
prevention setting may select for the outgrowth of EGFR or
Her2 activated cancer cells that ultimately become ER- can-
cers. Experimental and clinical evidence support a model
where tamoxifen can act as an agonist in a small fraction of
cancers. Osborne and colleagues [30,31] have demonstrated
that exposure to tamoxifen may accelerate the growth of
tumors that are AIB1+. Jones and colleagues have shown that
tamoxifen can be an agonist for the outgrowth of ER- hyperpla-
sias and cancers in the MMTV-Cre Brca1 conditional exon 11
deletion model. An analogous situation could exist for precan-
cerous cells [30,31].
In summary, the available data makes it difficult to exclude our
hypothesis. Swain and colleagues [5] show that the ER status
of primary tumors predicts the ER status of contralateral can-
cers that develop; however, women exposed to tamoxifen are
less likely to develop ER+ tumors. The studies by Osborne et
al. [30,31] suggest that the status of the first tumor does not
predict the status of the second tumor, and that tamoxifen
reduces the risk of a second tumor arising. Although these
numbers are small, they suggest that ER- tumors arise prefer-
entially because ER+ tumors are preferentially suppressed.
Overview data suggest that exposure to tamoxifen has a lesser
effect on the emergence of ER- tumors [1]. However, pro-
longed exposure to tamoxifen in the setting of early cancer
increases the risk of cancers arising, although the ER status of
those tumors is not known nor discoverable (J Costantino, per-
sonal communication). None of these observations preclude
the possibility that some ER- tumors are prevented and that
some ER- tumors may be stimulated by exposure to tamoxifen.
This paper was designed to raise awareness among scientists
and clinician researchers that there is another hypothesis that
may explain the observed data, and to encourage them to be
alert for and to explore observations of tamoxifen induced ER-
cancers.
Conclusion
We have shown that the BCPT and MORE data support the
possibility that tamoxifen may exert selection pressure on
some cells for the emergence of ER- cancers with activation of
mitogenic signaling pathways. It is possible that these results
Table 3
Calculation of Z using prevention trial data
Risk reduction Za
BCPT MORE
50% 23.5% 26.6%
60% 20.1% 22.7%
70% 16.2% 18.2%
80% 11.6% 13.1%
90% 6.3% 7.1%
aZ is the rate of transformation from ER+ to ER- tumors. BCPT, 
Breast Cancer Prevention Trial; MORE, Multiple Outcomes of 
Raloxifene.Available online http://breast-cancer-research.com/content/7/6/R1153
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are a mathematical coincidence, or an artifact of the data. If,
however, the proposed hypothesis were true, the clinical impli-
cation is that while most women at high risk benefit from
tamoxifen prophylaxis, there is a subset of women who would
not benefit and might have ER- tumor transformation acceler-
ated by prophylactic treatment with tamoxifen. These con-
cepts provide stimulus for future investigations to identify the
tumor cell phenotypes that differ in their susceptibility to pre-
ventive agents like tamoxifen. There may be subpopulations
within normal or dysplastic but premalignant breast epithelium
for which tamoxifen alone is insufficient prevention. It may be
appropriate to limit tamoxifen therapy to the prevention of the
most susceptible lesions, such as atypical ductal hyperplasia
in which tamoxifen can reduce the risk of subsequent invasive
disease by 80% [4]. We need to identify how carcinogens
influence discrete cell subpopulations in the normal and atyp-
ical breast epithelium and to identify the susceptible cell types
in order to tailor prevention efforts accordingly. Tamoxifen is
likely to remain an important chemopreventive agent, particu-
larly in the premenopausal setting. Thus, this hypothesis may
help us to consider other combinations of agents for preven-
tion, such as combinations of tamoxifen with small molecule
inhibitors that target the EGFR family or novel receptor tyro-
sine kinases. More importantly, it should encourage the design
of prevention interventions in a setting where we can follow
biomarkers and prospectively test the hypothesis presented in
this paper.
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